Instil Bio(US:TIL) TMX Newsfile·2026-01-20 20:03Core Viewpoint - Instil Bio, Inc. is under investigation for potential violations of federal securities laws following a significant drop in stock price after the announcement of the discontinuation of clinical development for AXN-2510 [1][2]. Group 1: Company Developments - Instil Bio's subsidiary, Axion Bio, Inc., has decided to discontinue the clinical development of AXN-2510 and has terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals [2]. - Following the announcement on January 6, 2026, Instil's stock price fell over 45% [2]. Group 2: Legal and Investigation Aspects - Levi & Korsinsky has commenced an investigation into Instil Bio regarding potential violations of federal securities laws, inviting affected investors to explore recovery options [1][3]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].